Abstract 613P
Background
The aim of this study was to determine the clinical characteristics and treatment outcomes of women with recurrent uterine leiomyosarcoma (uLMS).
Methods
We conducted a retrospective cohort study to evaluate the clinical characteristics and treatment outcomes of women with recurrent uLMS and identify prognostic factors.
Results
Overall, 71 patients with first recurrent of uLMS were included in our study. The FIGO 2008 distribution by stage at initial presentation was: stage I in 55 patients (77.5%), stage II in 8 patients (11.3%), stage III in 3 patients (4.2%) and stage IV in 5 patients (7.0%). The median time from the initial diagnoses to first recurrence was 16.3 months (range: 1.0-161.9 months). 33.8% (24/71) patients experience recurrence after initial diagnoses within 12 months. The most common site of first recurrence was the abdominal/pelvic peritoneum, diagnosed in 47 (66.2%) patients. In the entire cohort, 19 patients (26.8%) received systematic therapy and 52 patients (73.2%) received secondary cytoreductive surgery (SCS). In SCS subgroup (n=52), a complete resection with no residual disease was reported in 47 patients (90.4%). 38.5% (20/52) patients had received non-genital organ surgeries. 10 (19.2%) patients had received thoracic surgery because of lung-only recurrence. Bowel, bladder surgeries were performed in 15.4%, 5.8% of the cases, respectively. 1 (1.9%) patient had received liver surgery. 34.6% patients had estimated blood loss more than 500 ml. The median follow-up duration was 38.7 months (range: 2.7-317.6 months). 5-year OS for the entire cohort was 52.9%. Patients experienced first recurrence after initial diagnoses within 12 months had a worse 5-year OS than those after 12 months (17.0% vs 69.1%, P<0.001). 5-year OS for the SCS and non-SCS subgroup was 62.0% and 28.0%, respectively (P<0.001). Multivariate analysis showed time to fist recurrence within 12 months (HR=4.60, 95% CI: 1.49-14.4, P = 0.008) was an independent predictor of decreased 5-year OS in SCS subgroup.
Conclusions
The current study shows that SCS is an important treatment choice for these patients and seems to have benefited patients. Time to fist recurrence within 12 months is an independent predictor of decreased 5-year OS in SCS subgroup.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hua Yuan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.